The Canadian Center for Vaccinology (CCfV) is Canada’s only fully integrated collaborative vaccine research facility spanning clinical trials/evaluation, basic science, and social science. CCfV serves as a critical “academic pipeline” for Canadian vaccine priorities – from the development of promising new vaccine candidates from Canadian and international companies, to applied public health research that supports timely public health decision-making. CCfV leads Phase 1–4 clinical trials in all age populations, from infants to the elderly. Over the past 15 years, the center has developed a specialization in early phase vaccine clinical trials, with more than 25 such trials. In 2020-21 CCfV was approached to undertake five Phase 1 trials for “made in Canada” COVID-19 vaccines, three of which are completed. Currently CCfV is leading or collaborating on 15 COVID projects including both national and international studies on pandemic policies and programs in equity-deserving populations, five COVID adult and one pediatric vaccine clinical trials; two international COVID vaccine clinical trials, and six national vaccine safety and surveillance studies in various populations. CCfV clinical facilities include a 7,000 sq. ft. full-containment Vaccine Challenge Unit (VCU) specifically designed for controlled human infection studies – the first of only two such units in Canada. CCfV investigators are currently conducting a pertussis human challenge study in the facility, in partnership with the US Centers for Disease Control and Prevention funded by the US National Institutes of Health and CDC.
Menu
